SAMIR ISHAK: Open Payments
NPI 1548257488 · PORTLAND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,770 in 87 payments from 10 companies in 2025. Trend: 2023 $1,028 · 2024 $1,150 · 2025 $1,770
Food & beverage: $1,660Education: $109
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $454 |
| E.R. Squibb & Sons, L.L.C. | 28 | $402 |
| Teva Pharmaceuticals USA, Inc. | 13 | $351 |
| Alkermes, Inc. | 9 | $188 |
| Axsome Therapeutics, Inc. | 5 | $116 |
| Neurocrine BioSciences, Inc. | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $91 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| ABBVIE INC. | 1 | $16 |
Products named: COBENFY, ABILIFY ASIMTUFII, UZEDY, ARISTADA, ABILIFY MAINTENA, Auvelity, INGREZZA, REXULTI.
Industry payments across IN — which companies pay providers there.
